Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today announced that the U.S. Food and Drug ...
It's been a long time since I've written about the deceptive narratives around placebos promoted by supporters of alternative ...
This important study uses a tripartite transdiagnostic computational framework to distinguish depression-specific, anxiety-specific, and shared psychopathology dimensions, in their relationships to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results